
Elena L Chernolovskaya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10100204/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Current Development of siRNA Bioconjugates: From Research to the Clinic. Frontiers in Pharmacology, 2019, 10, 444.	3.5	147
2	Selective Protection of Nuclease-Sensitive Sites in siRNA Prolongs Silencing Effect. Oligonucleotides, 2009, 19, 191-202.	2.7	89
3	Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Research, 2012, 40, 2330-2344.	14.5	77
4	Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene. Molecular Therapy - Nucleic Acids, 2017, 6, 209-220.	5.1	64
5	Targeted delivery of nucleic acids into xenograft tumors mediated by novel folate-equipped liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 123, 59-70.	4.3	32
6	Short Double-Stranded RNA with Immunostimulatory Activity: Sequence Dependence. Nucleic Acid Therapeutics, 2012, 22, 196-204.	3.6	29
7	A novel expression cassette delivers efficient production of exclusively tetrameric human butyrylcholinesterase with improved pharmacokinetics for protection against organophosphate poisoning. Biochimie, 2015, 118, 51-59.	2.6	25
8	Immunotherapy of hepatocellular carcinoma with small double-stranded RNA. BMC Cancer, 2014, 14, 338.	2.6	22
9	Antitumor and Antimetastatic Effect of Small Immunostimulatory RNA against B16 Melanoma in Mice. PLoS ONE, 2016, 11, e0150751.	2.5	22
10	Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma. Science Advances, 2018, 4, eaau4580.	10.3	19
11	Silencing activity of 2′-O-methyl modified anti-MDR1 siRNAs with mismatches in the central part of the duplexes. FEBS Letters, 2011, 585, 2352-2356.	2.8	14
12	Activation of Innate Immunity by Therapeutic Nucleic Acids. International Journal of Molecular Sciences, 2021, 22, 13360.	4.1	13
13	Novel PEGylated Liposomes Enhance Immunostimulating Activity of isRNA. Molecules, 2018, 23, 3101.	3.8	12
14	Transport Oligonucleotides—A Novel System for Intracellular Delivery of Antisense Therapeutics. Molecules, 2020, 25, 3663.	3.8	12
15	42―and 63â€bp antiâ€MDR1â€siRNAs bearing 2′â€OMe modifications in nucleaseâ€sensitive sites induce sp potent gene silencing. FEBS Letters, 2014, 588, 1037-1043.	ecific and	11
16	Folate-Equipped Cationic Liposomes Deliver Anti-MDR1-siRNA to the Tumor and Increase the Efficiency of Chemotherapy. Pharmaceutics, 2021, 13, 1252.	4.5	11
17	Fluorophore Labeling Affects the Cellular Accumulation and Gene Silencing Activity of Cholesterol-Modified siRNAs <i>In Vitro</i> . Nucleic Acid Therapeutics, 2019, 29, 33-43.	3.6	10
18	Arrest of Cancer Cell Proliferation by dsRNAs. Annals of the New York Academy of Sciences, 2006, 1091, 425-436.	3.8	8

#	Article	IF	CITATIONS
19	Nucleaseâ€resistant 63â€bp trimeric si <scp>RNA</scp> s simultaneously silence three different genes in tumor cells. FEBS Letters, 2018, 592, 122-129.	2.8	7
20	Inhibition of Human Cancer-Cell Proliferation by Long Double-Stranded RNAs. Oligonucleotides, 2009, 19, 31-40.	2.7	6
21	Trimeric Small Interfering RNAs and Their Cholesterol-Containing Conjugates Exhibit Improved Accumulation in Tumors, but Dramatically Reduced Silencing Activity. Molecules, 2020, 25, 1877.	3.8	6
22	Immunostimulating RNA Delivered by P1500 PEGylated Cationic Liposomes Limits Influenza Infection in C57Bl/6 Mice. Pharmaceutics, 2020, 12, 875.	4.5	5
23	Molecular Mechanism of the Antiproliferative Activity of Short Immunostimulating dsRNA. Frontiers in Oncology, 2019, 9, 1454.	2.8	3